DÄ internationalArchive33/2007Benign Prostatic Hyperplasia

Review article

Benign Prostatic Hyperplasia

Terminology and Assessment

Dtsch Arztebl 2007; 104(33): A-2261

Oelke, M; Höfner, K; Jonas, U; Laval, K; Tunn, U

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Berges R, Dreikorn K, Höfner K et al.: Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe [A] 2003; 42: 584–90. MEDLINE
2. McNeal JE: Regional morphology and pathology of the prostate. Am J Clin Pathol 1968; 49: 347–57. MEDLINE
3. Roehrborn CG, McConnell JD: Etiology, pathophysilogy, epidemiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds.): Campbell´s Urology. Philadelphia, London, New York: Saunders 2002; 1297–336.
4. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–9. MEDLINE
5. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351–8. MEDLINE
6. Rosier PF, de la Rosette JJ: Is there a correlation between prostate size and bladder outlet obstruction? World J Urol 1995; 13: 9–13. MEDLINE
7. van Venrooij GE, Boon TA, de Gier RP: International prostate symptom score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms. J Urol 1995; 153: 1516–9. MEDLINE
8. Hald T: Urodynamics in benign prostatic hyperplasia. A survey. Prostate 1989; 2 (Suppl.): 69–77. MEDLINE
9. Berges RR, Pientka L, Höfner K, Senge T, Jonas U: Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 2001; 39: 682–7. MEDLINE
10. Peters TJ, Donovan JL, Kay HE et al.: The International Continence Society „Benign Prostatic Hyperplasia“ Study: the bothersomeness of urinary symptoms. J Urol 1997; 157: 885–9. MEDLINE
11. Jimenez-Cruz F: Identifying the patients at risk for disease progression. Eur Urol 2003; Suppl 2: 6–12.
12. Chancellor MB, Rivas DA, Keeley FX, Lotfi MA, Gomella LG: Similarity of the American Urological Association Symptom Index among men with benign prostatic hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br J Urol 1994; 74: 200–3. MEDLINE
13. Ameda K, Sullivan MP, Bae RJ, Yalla SV: Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999; 162: 142–6. MEDLINE
14. Reynard JM, Yang Q, Donovan JL et al.: The ICS-“BPH“ Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82: 619–23. MEDLINE
15. Gilpin SA, Gosling JA, Barnard RJ: Morphological and morphometric studies of the human obstructed, trabeculated urinary bladder. Br J Urol 1985; 57: 525–9. MEDLINE
16. Kojima M, Inui E, Ochiai A et al.: Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J Urol 1997; 158: 89–93. MEDLINE
17. McConnell JD, Barry MJ, Bruskewitz RC et al.: Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline No.8, AHCPR Publication No. 94-0582, U.S. Department of Health and Human Services, Agency for Health Care Policy and Research, Rockville Maryland 1994.
18. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC: Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243–7. MEDLINE
19. Jacobsen SJ, Jacobsen DJ, Girman CJ et al.: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481–7. MEDLINE
20. Leblanc G, Tessier J, Schick E: The importance and significance of post-micturitional bladder residue in the evaluation of prostism. Prog Urol 1995; 5: 511–4. MEDLINE
21. Hampson SJ, Noble JG, Rickards D, Milroy EJ: Does residual urine redispose to urinary tract infection? Br J Urol 1992; 70: 506–8. MEDLINE
22. Akdas A, Tarcan T, Turkeri L, Cevik I, Biren T, Ilker Y: The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific levels are less than 10 ng/ml. Eur Urol 1996; 29: 189–92. MEDLINE
23. McConnell JD, Roehrborn CG, Bautista OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–98. MEDLINE
24. Oelke M, Höfner K, Wiese B, Grünewald V, Jonas U: Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol 2002; 19: 443–52. MEDLINE
25. Höfner K, Jonas U: Urodynamics in benign prostatic hyperplasia. Curr Opion Urol 1996; 6: 184–8.